Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical tria… Read more
Market Cap & Net Worth: Compugen (CGEN)
Compugen (NASDAQ:CGEN) has a market capitalization of $212.33 Million ($212.33 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16131 globally and #6249 in its home market, demonstrating a 5.58% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Compugen's stock price $2.27 by its total outstanding shares 93535357 (93.54 Million).
Compugen Market Cap History: 2015 to 2026
Compugen's market capitalization history from 2015 to 2026. Data shows change from $597.69 Million to $212.33 Million (-9.80% CAGR).
Index Memberships
Compugen is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.01% | #434 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1522 of 3165 |
Weight: Compugen's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Compugen Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Compugen's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.14x
Compugen's market cap is 5.14 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $597.69 Million | $9.28 Million | -$20.16 Million | 64.43x | N/A |
| 2016 | $477.03 Million | $712.00K | -$31.51 Million | 669.99x | N/A |
| 2018 | $202.97 Million | $17.80 Million | -$22.60 Million | 11.40x | N/A |
| 2020 | $1.13 Billion | $2.00 Million | -$27.26 Million | 566.36x | N/A |
| 2021 | $402.20 Million | $6.00 Million | -$32.87 Million | 67.03x | N/A |
| 2022 | $66.94 Million | $7.50 Million | -$33.69 Million | 8.93x | N/A |
| 2023 | $185.20 Million | $33.46 Million | -$18.75 Million | 5.54x | N/A |
| 2024 | $143.11 Million | $27.86 Million | -$14.23 Million | 5.14x | N/A |
Competitor Companies of CGEN by Market Capitalization
Companies near Compugen in the global market cap rankings as of March 18, 2026.
Key companies related to Compugen by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Compugen Historical Marketcap From 2015 to 2026
Between 2015 and today, Compugen's market cap moved from $597.69 Million to $ 212.33 Million, with a yearly change of -9.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $212.33 Million | +48.37% |
| 2025 | $143.11 Million | 0.00% |
| 2024 | $143.11 Million | -22.73% |
| 2023 | $185.20 Million | +176.65% |
| 2022 | $66.94 Million | -83.36% |
| 2021 | $402.20 Million | -64.49% |
| 2020 | $1.13 Billion | +103.19% |
| 2019 | $557.47 Million | +174.65% |
| 2018 | $202.97 Million | -13.20% |
| 2017 | $233.84 Million | -50.98% |
| 2016 | $477.03 Million | -20.19% |
| 2015 | $597.69 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Compugen was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $212.33 Million USD |
| MoneyControl | $212.33 Million USD |
| MarketWatch | $212.33 Million USD |
| marketcap.company | $212.33 Million USD |
| Reuters | $212.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.